Analysis of Re-biopsy Specimens in Advanced NSCLC With Acquired Resistance of EGFR-TKI Targeted Therapy
NCT03309462
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Interventions
DEVICE:
Miseq sequencer
Sponsor
Shanghai Chest Hospital